Pluslife Showcased Innovative Molecular Diagnostics at WHX Lagos & WHX Labs Lagos 2025

From June 2 to 4, 2025, Pluslife, a leading Chinese company in the field of molecular diagnostics, made a strong appearance at WHX Lagos & WHX Labs Lagos 2025, held at the Landmark Centre in Lagos, Nigeria. As one of the key medical events in West Africa, the exhibition attracted representatives from healthcare institutions, government officials, procurement agencies, and international partners across the continent.

Advancing Primary Care with Innovative Technologies

In the context of limited primary care resources and a high burden of infectious diseases, there is a growing global need for diagnostic solutions that are rapid, accurate, and affordable at the primary care level. Pluslife addresses this critical gap through its proprietary RHAM technology—an innovative one-step molecular amplification system that integrates optimized enzyme formulations to streamline workflows and enhance amplification efficiency. The result is a low-cost, high-sensitivity, and user-friendly near-patient molecular diagnostics platform, tailored for resource-constrained settings.

Performance Validated in Multi-Country Clinical Study

Within a multi-center clinical study spanning over 10 low- and middle-income countries (LMICs), Pluslife’s Tuberculosis (TB) nucleic acid test was evaluated against sputum culture as the reference standard for tuberculosis. The results demonstrated a sensitivity of 89.9% (95% CI: 80.2–95.8) and a specificity of 98.2% (95% CI: 95.5–99.3), significantly outperforming conventional smear microscopy (sensitivity: 67.1%).

Dual-Specimen TB Test Gains Attention

Pluslife’s molecular tuberculosis nucleic acid test, compatible with both sputum and tongue swab specimens, attracted considerable attention at the exhibition. The inclusion of tongue swab testing offers an accessible alternative for populations unable to expectorate, such as children, the elderly, and immunocompromised individuals. According to data presented at the 55th Union World Conference on Lung Health in 2024, Pluslife’s tongue swab assay demonstrated sensitivity and specificity levels well above the WHO’s target performance requirements for non-sputum near-patient TB diagnostics.

Real-World Deployment Demonstrates Practical Benefits

In real-world deployment, this dual-specimen platform offers tangible advantages over centralized testing workflows, including faster turnaround time, higher case detection rates, and reduced overall cost. It provides a practical path toward building more effective and sustainable primary-level disease surveillance systems.

A Diversified Portfolio for a Range of Use Scenarios

Pluslife is working to reshape the diagnostics foundation of primary healthcare systems worldwide. By enabling earlier detection and faster response to public health threats, we support stronger frontline health capacity. Looking ahead, Pluslife will continue to expand its product pipeline to meet diverse diagnostic needs and contribute to enhanced global preparedness and response in primary healthcare.